Clinical Assessment & Management — Mixed P. falciparum + P. vivax Malaria

⚠️ Severity Classification — This is SEVERE Malaria

Assessment of Current Management

✅ What is Correct

1. Falcigo (artesunate) IV — Correct choice. WHO (2023) strong recommendation: "Adults and children with severe malaria should be treated with intravenous or intramuscular artesunate for at least 24 hours and until they can tolerate oral medication."
   • Artesunate is superior to quinine (better mortality outcomes, better tolerated).
   • Dose check: For patients >20 kg: 2.4 mg/kg IV at 0h, 12h, 24h, then every 24h. Confirm the correct weight-based dose is being used. At ~17 years old / estimated ~50–60 kg: this is ~120–144 mg per dose.
2. IV Fluids — Appropriate for hypotension/shock management.
3. Paracetamol 1 g — Appropriate antipyretic.
4. Doxycycline — Appropriate as a partner drug for falciparum (alongside artesunate for a full 7-day course). Note: this is correct because the patient is ≥8 years old. Caution: doxycycline is IV/oral — confirm route of administration since patient is vomiting.

⚠️ Concerns & Gaps in Current Management

• Aggressive fluid resuscitation in severe malaria increases the risk of acute pulmonary edema and ARDS — a leading cause of death in severe malaria.
• WHO 2023 recommends cautious fluid replacement in severe malaria — not the same as septic shock fluid protocols.
• Recommendation: Monitor for fluid overload (increasing RR, oxygen saturation). The RR of 26/min already warrants caution. Consider reducing maintenance fluids and monitoring closely with pulse oximetry. Avoid exceeding maintenance unless there is clear evidence of dehydration/ongoing losses.

• Primaquine 0.25–0.5 mg/kg/day × 14 days is required for radical cure to prevent relapse.
• ⚠️ Critical prerequisite: Test for G6PD deficiency before starting primaquine. Primaquine causes severe hemolytic anemia in G6PD-deficient patients. In G6PD deficiency, use the weekly low-dose regimen (0.75 mg/kg once weekly × 8 weeks) or defer until G6PD status is confirmed.
• Primaquine should be started after the acute illness stabilizes and the patient can take oral medication.

• Artemether-lumefantrine (AL) — first choice
• OR Dihydroartemisinin-piperaquine (DHP)
• Continue doxycycline to complete the full 7-day course for the falciparum component.

• LFTs, serum bilirubin (assess for jaundice/hepatitis)
• Abdominal USG to evaluate hepatosplenomegaly, rule out splenic rupture (rare but life-threatening)

Summary Management Plan

IMMEDIATE:
• Continue IV artesunate (Falcigo) — confirm dosing at 2.4 mg/kg at 0h/12h/24h, then q24h
• Continue doxycycline (IV or oral when tolerating) — complete 7 days total
• Reassess fluid rate — cautious hydration given RR 26/min and risk of pulmonary edema
• SpO₂ monitoring, supplemental oxygen if <95%
• 4-hourly blood glucose monitoring
• Blood cultures if sepsis cannot be excluded

URGENT INVESTIGATIONS:
• Repeat thick/thin blood smear + parasite count
• CBC with differential, LFTs, RFTs, serum bilirubin
• Blood glucose, lactate
• G6PD level (required before primaquine)
• Coagulation profile (DIC screen)
• Abdominal USG (hepatosplenomegaly, rule out splenic rupture)

ONCE TOLERATING ORAL MEDICATION (after ≥24h IV artesunate):
• Switch to oral ACT (artemether-lumefantrine × 3 days)
• Continue doxycycline to complete 7-day course
• Add primaquine (after G6PD confirmed normal):
  - 0.25–0.5 mg/kg/day × 14 days for vivax radical cure

ONGOING:
• Daily CBC, parasitemia, renal/liver function
• Post-artesunate hemolysis monitoring at D7, D14, D21, D28
• Platelet transfusion threshold: <10,000/µL or active bleeding

Key Points for This Case

• Mixed falciparum + vivax: treat the falciparum aggressively (IV artesunate ≥24h, then oral ACT + doxycycline 7 days); add primaquine after recovery for vivax radical cure.
• Do not equate this with uncomplicated malaria — the hemodynamic instability, tachypnoea, and vomiting classify it as severe.
• Fluid management is a balancing act — underfill worsens shock; overfill causes pulmonary edema and ARDS. Target euvolemia with close monitoring.
• The textbook caution is clear: "If the laboratory reports a mixed infection involving P. falciparum and P. vivax, the treatment must eradicate not only P. falciparum from the erythrocytes but also the liver stages of P. vivax to avoid relapses." — Medical Microbiology, 9e